Windgap Medical Appoints Max Meehan as Director of Corporate Development and Strategy
Watertown, MA, September 21, 2023 — Windgap Medical is pleased to announce the appointment of Max Meehan as the Director of Corporate Development and Strategy. Meehan joined Windgap on September 1. He will lead capital raising and allocation activities as well as company strategy.
“Max’s experiences as a life sciences investor and as an operating executive bring significant value to Windgap’s leadership team,” said Aaron Mann, Windgap’s CEO. “I look forward to working with Max on Windgap’s capital strategy and strategic development over the next several quarters.”
Prior to joining Windgap, Meehan executed the successful carve-out of 3M’s drug delivery business and creation of Kindeva Drug Delivery, a CDMO focused on complex drug delivery challenges. Prior to Kindeva, Meehan was a member of the investment team at Altaris Capital Partners, where he evaluated and executed private equity transactions in the biopharma industry. Before Altaris, Max worked in the healthcare practice at Bain & Company, with relevant experience in pharmaceuticals, clinical diagnostics, and medical devices. He holds an MBA and Masters in Biotechnology from Harvard University. He also holds an AB in Chemistry and Chemical Biology from Harvard College.
“Patients deserve more innovation in the drug delivery space,” said Meehan. “I am excited join Windgap as we enter this next phase of growth.”
ABOUT WINDGAP MEDICAL, INC
Windgap Medical, Inc. offers autoinjector platforms that simplify, automate, and accelerate the delivery of complex injectables, freeing patients, families, and potential cures from the limitations of current medical delivery technology. With an innovative design, development, and manufacturing process and an industry-leading team, Windgap’s “instant solutions” create a new frontier of pharmaceuticals for partners seeking to harness its wet-dry drug delivery technology and an increased speed to market. Its first product is for the administration of epinephrine for anaphylaxis, with additional products under development in a variety of markets.
Windgap Medical, Inc. is an emerging, privately held pharmaceutical company in the Greater Boston area.
FOR QUESTIONS, CONTACT:
Aaron Mann
Windgap Medical, Inc.
(339) 232-7759
press@windgapmedical.com